Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
B
Boston Bio Systems Ltd
Score 48/100• Risky
Boston Bio Systems Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health42/100
Valuation 100/100 · PB 0.9055
Technical Avoid
1M -2.43% 6M -12.4% 1Y -61.581%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#241
View details ➜
B
Beta Drugs Ltd
Score 48/100• Decent
Beta Drugs Ltd shows potential but faces challenges in growth consistency and market sentiment.
Company’s Health94/100
Valuation 20/100 · PB 8.7654
Technical Avoid
1M -6.071% 6M -7.342% 1Y -6.515%
Confidence100%
No promoter pledgeDecent revenue growth
#242
View details ➜
B
Beryl Drugs Ltd
Score 48/100• Risky
Beryl Drugs Ltd presents a risky investment with moderate growth potential but significant challenges in profitability and valuation.
Company’s Health59/100
Valuation 80/100 · PB 1.2055
Technical Avoid
1M -10.181% 6M 0.133% 1Y -44.439%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#243
View details ➜
A
Auro Laboratories Ltd
Score 48/100• Decent
Auro Laboratories Ltd shows potential but faces challenges in growth consistency and market valuation.
Company’s Health53/100
Valuation 40/100 · PB 3.183
Technical Avoid
1M -12.106% 6M -11.619% 1Y -1.57%
Confidence100%
No promoter pledge
Weak ROE
#244
View details ➜
A
Astrazeneca Pharma India Ltd
Score 48/100• Decent
Astrazeneca Pharma India Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health90/100
Valuation 20/100 · PB 29.6894
Technical Avoid
1M 1.311% 6M 3.099% 1Y 20.123%
Confidence100%
Low leverage (D/E)No promoter pledge
Thin margins
#245
View details ➜
A
Astonea Labs Ltd
Score 48/100• Risky
Astonea Labs Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health79/100
Valuation 20/100 · PB 14.0425
Technical Avoid
1M -8% 6M 17.987% 1Y 17.987%
Confidence100%
No promoter pledgeDecent revenue growth
High debt/equityThin margins
#246
View details ➜
A
Astal Laboratories Ltd
Score 48/100• Risky
Astal Laboratories Ltd shows potential but faces significant risks and challenges in growth and profitability.
Company’s Health74/100
Valuation 60/100 · PB 2.9677
Technical Momentum
1M 14.868% 6M 18.264% 1Y -5.927%
Confidence100%
Low leverage (D/E)No promoter pledge
#247
View details ➜
P
Pharmaids Pharmaceuticals Ltd
Score 48/100• Decent
Pharmaids Pharmaceuticals Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics.
Company’s Health48/100
Valuation 40/100 · PB 3.0398
Technical Avoid
1M -26.742% 6M -29.593% 1Y 21.051%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#248
View details ➜
P
Parabolic Drugs Ltd
Score 48/100• Risky
Parabolic Drugs Ltd presents several risks with limited growth prospects and high valuation concerns, making it a risky investment.
Company’s Health14/100
Valuation 100/100 · PB -0.0398
Technical Avoid
1M 0% 6M 0% 1Y 0%
Confidence100%
Reasonable PB valuation
Promoter pledge presentThin margins
#249
View details ➜
O
Oxygenta Pharmaceutical Ltd
Score 48/100• Risky
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
Company’s Health71/100
Valuation 100/100 · PB -8.8388
Technical Avoid
1M -24.017% 6M -20.558% 1Y -34.228%
Confidence100%
No promoter pledgeDecent revenue growth
Thin margins
#250
View details ➜
O
Orchid Pharma Ltd
Score 48/100• Risky
Orchid Pharma Ltd presents several risks with inconsistent growth and high debt levels, making it a risky investment.
Company’s Health72/100
Valuation 60/100 · PB 2.8894
Technical Avoid
1M 2.664% 6M -4.46% 1Y -47.059%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#251
View details ➜
N
Novelix Pharmaceuticals Ltd
Score 48/100• Risky
Novelix Pharmaceuticals Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
Company’s Health63/100
Valuation 40/100 · PB 3.3088
Technical Avoid
1M -1.672% 6M 50.62% 1Y 82.93%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#252
View details ➜
N
Norris Medicines Ltd
Score 48/100• Risky
Norris Medicines Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health37/100
Valuation 100/100 · PB -1.0835
Technical Avoid
1M -7.371% 6M -15.174% 1Y -19.5%
Confidence100%
No promoter pledgeReasonable PB valuation
Thin margins
#253
View details ➜
N
Nexus Surgical and Medicare Ltd
Score 48/100• Risky
Nexus Surgical and Medicare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health80/100
Valuation 20/100 · PB 8.564
Technical Avoid
1M -12.282% 6M 7.379% 1Y -7.987%
Confidence100%
Low leverage (D/E)No promoter pledge
#254
View details ➜
M
Morepen Laboratories Ltd
Score 48/100• Risky
Morepen Laboratories Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
Company’s Health75/100
Valuation 60/100 · PB 2.22
Technical Avoid
1M -10.735% 6M -8.208% 1Y -46.136%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#255
View details ➜
Showing 241 to 255 of 301 (21 Pages)